What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination

The process of tumorigenesis leaves a series of indelible genetic changes in tumor cells, that when expressed, have the potential to be tumor-specific immune targets. Neoantigen vaccines that capitalize on this potential immunogenicity have shown efficacy in preclinical models and have now entered c...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2022-12, Vol.11 (1), p.2038403-2038403
Main Authors: Redwood, Alec J., Dick, Ian M., Creaney, Jenette, Robinson, Bruce W. S.
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - genetics
Cancer Vaccines - therapeutic use
Humans
Immunotherapy
Neoantigen
neoantigen vaccine
Neoplasms - drug therapy
Review
Vaccination
vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The process of tumorigenesis leaves a series of indelible genetic changes in tumor cells, that when expressed, have the potential to be tumor-specific immune targets. Neoantigen vaccines that capitalize on this potential immunogenicity have shown efficacy in preclinical models and have now entered clinical trials. Here we discuss the status of personalized neoantigen vaccines and the current major challenges to this nascent field. In particular, we focus on the types of antigens that can be targeted by vaccination and on the role that preexisting immunosuppression, and in particular T-cell exhaustion, will play in the development of effective cancer vaccines.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.1080/2162402X.2022.2038403